工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
调控 TCR 衍生疗法的策略与规则
英文原题：Strategies and rules for tuning TCR-derived therapy.
查看英文原题
Strategies and rules for tuning TCR-derived therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T细胞工程化已革新癌症免疫治疗。尤其是使用携带工程化T细胞受体（TCR-T）的T细胞，为实体瘤治疗提供了有利途径。然而，临床缓解率有限、脱靶效应和肿瘤免疫抑制微环境等重大挑战，阻碍该方法转化至临床。本综述旨在指导TCR-T研究者：获得特异性TCR序列后，在实体瘤治疗中需考虑几个关键问题：（1）是否需要进行亲和力成熟；如需进行，应采用哪些参数判断疗效是否提高；（2）可加入哪些改造以对抗肿瘤抑制性微环境、增强特异性T细胞功能，这些改造的安全性如何；（3）未来TCR-T细胞疗法有哪些新形式和可能性。
展开英文摘要原文
Manipulation of T cells has revolutionized cancer immunotherapy.
Notably, the use of T cells carrying engineered T cell receptors (TCR-T) offers a favourable therapeutic pathway, particularly in the treatment of solid tumours.
However, major challenges such as limited clinical response efficacy, off-target effects and tumour immunosuppressive microenvironment have hindered the clinical translation of this approach. In this review, we mainly want to guide TCR-T investigators on several major issues they face in the treatment of solid tumours after obtaining specific TCR sequences: (1) whether we have to undergo affinity maturation or not, and what parameter we should use as a criterion for being more effective.
(2) What modifications can be added to counteract the tumour inhibitory microenvironment to make our specific T cells to be more effective and what is the safety profile of such modifications? (3) What are the new forms and possibilities for TCR-T cell therapy in the future?
论文信息
- 作者
- Mo G、Lu X、Wu S、Zhu W
- 单位
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Expert reviews in molecular medicine2023 Dec 14
- 原文标识
- PubMed 38095091 · DOI 10.1017/erm.2023.27
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →